logo

Unity Biotechnology, Inc. (UBX)



Trade UBX now with
  Date
  Headline
9/19/2022 8:30:21 AM UNITY Biotechnology Completes Enrollment In Phase 2 ENVISION Study Of UBX1325 In Wet Age-related Macular Degeneration
8/19/2022 9:24:52 AM Wedbush Is Raising Unity Biotechnology, Inc. (UBX) FY23 Estimate To -0.61 From -1.42
8/19/2022 9:24:24 AM Wedbush Is Raising Unity Biotechnology, Inc. (UBX) Q4 23 Estimate To -0.17 From -0.41
8/19/2022 9:24:04 AM Wedbush Is Raising Unity Biotechnology, Inc. (UBX) Q3 23 Estimate To -0.16 From -0.37
8/19/2022 9:23:47 AM Wedbush Is Raising Unity Biotechnology, Inc. (UBX) Q2 23 Estimate To -0.15 From -0.34
8/19/2022 9:23:22 AM Wedbush Is Raising Unity Biotechnology, Inc. (UBX) Q1 23 Estimate To -0.14 From -0.30
8/19/2022 9:22:57 AM Wedbush Is Increasing Unity Biotechnology, Inc. (UBX) FY22 Estimate To -0.72 From -0.94
8/19/2022 9:22:33 AM Wedbush Is Raising Unity Biotechnology, Inc. (UBX) Q4 22 Estimate To -0.13 From -0.25
8/19/2022 9:22:08 AM Wedbush Is Raising Unity Biotechnology, Inc. (UBX) Q3 22 Estimate To -0.11 From -0.22
8/19/2022 9:20:52 AM Wedbush Reiterates Unity Biotechnology, Inc. (UBX) At Outperform With $4 Price Target
8/12/2022 7:20:17 AM UNITY Biotechnology Announces Positive Data In Phase 2 BEHOLD Study Of UBX1325 In Diabetic Macular Edema
12/15/2021 4:35:17 PM Wedbush Starts Unity Biotechnology, Inc. (UBX) At Outperform With $4 Price Target
10/5/2021 7:14:12 AM UNITY Biotechnology Announces Positive 12-Week Data From Phase 1 Trial Of UBX1325 In Advanced Vascular Eye Disease
7/6/2021 7:27:33 AM UNITY Biotechnology Announces Positive Data From Phase 1 Trial Of UBX1325 In Advanced Vascular Eye Disease